May Health

Executive Summary

May Health is a French medical device company headquartered in Paris, founded in 2020, dedicated to advancing women's health through a novel, hormone-free treatment for Polycystic Ovary Syndrome (PCOS). The company's core technology, the Anavi System, enables a one-time outpatient procedure called Ovarian Rebalancing, which restores ovulation by performing targeted ovarian ablation. This approach addresses a significant unmet need, as PCOS affects approximately 10% of women of reproductive age globally, and current treatments often rely on chronic hormone therapy or invasive surgery. By offering a minimally invasive, drug-free alternative, May Health has the potential to improve clinical outcomes and quality of life for millions of women. <br><br>The company is still in a relatively early stage, with no disclosed funding or valuation data, and lacks publicly available clinical trial results or regulatory approvals. However, its differentiated technology positions it well within the fast-growing women's health and medical device sectors. Key value drivers include successful completion of clinical studies, obtaining CE marking for European commercialization, and eventual FDA clearance for the U.S. market. Strategic partnerships with reproductive health clinics or larger medtech firms could also accelerate adoption. Given the early stage, May Health presents a high-risk, high-reward opportunity with meaningful upside if clinical and regulatory milestones are achieved.

Upcoming Catalysts (preview)

• Q2 2027Release of pivotal clinical trial data for Ovarian Rebalancing40% success
• Q4 2027CE mark submission and approval for Anavi System35% success
• Q3 2027Series A or B financing round to support commercialization50% success